(v) Avelumab: Avelumab, a human monoclonal IgG1 antibody targeted against PD-L1 was developed by Merck, Darmstadt, Germany and currently is in Phase II for SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.